Diabetes Type 2

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

Your daily dose of the clinical news you may have missed.

ACC.24: Results of STEP HFpEF DM showed significant improvement in quality of life measures among adults with obesity-related HFpEF and type 2 diabetes.

In a population cohort of adults with T2D, a BMI above "normal" range appeared more likely to protect against CV death in those older than age 65 years than those younger.

Your daily dose of the clinical news you may have missed.

Longer duration of remission was associated with a greater reduction in CKD and CVD risk, according to a post hoc analysis of the Look AHEAD study.

LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.

Primary care plays an essential role in identifying CKD, monitoring and slowing disease progression, and providing timely referral, when indicated, to nephrology.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

One study showed a significant 1.5% decrease in HbA1c 6 months after participants taking a GLP-1 RA started using the Freestyle Libre system.

The Dexcom system is for adults over the age of 18 years who do not use insulin, such as individuals with T2D who use oral medications, a US population of 25 million.

Semaglutide 1.0 mg was superior to placebo across the FLOW trial's 5-part primary endpoint with both CKD and CVD components contributing to risk reduction, said Novo Nordisk.

The 3-year risk of rapid progression from CKD stage G3 was 15% in a large Danish population. Study authors identified accessible key risk factors to aid early detection.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Comprehensive management of T2D in primary care settings reduced risk of all-cause dementia by 28%, with lower HbA1c linked to lower, but still elevated risk.

Your daily dose of the clinical news you may have missed.

Acute, preventable diabetes complications days fell by 8.4% among participants enrolled in a preventive drug list benefit and by even more among low-income subscribers.

Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.

Preventive health screenings have yet to rebound to pre-COVID-19 levels and Asian adults appear to have fallen behind more than other racial/ethnic groups, a new study finds.

Your daily dose of the clinical news you may have missed.

Adolescents with overweight or obesity and baseline HbA1c 6.3%-6.4% were at 72-fold greater risk for T2D than those with HbA1c of 5.5%, a new cohort study finds.

Remission of T2D, regardless of duration of remission, was associated with reduced risk of diabetes-related CKD and CVD in a post hoc analysis of Look AHEAD.

The digital prescription therapeutic when used along with prescription diabetes therapies, can help reduce the costs of managing the disease and enhance standard of care.

The GLP-1 RAs Wegovy, Ozempic, Mounjaro, and Zepbound have taken up more real estate on the US map in some areas than others. Click to find out more.

Your daily dose of the clinical news you may have missed.

While the FDA's preliminary evaluation has not surfaced evidence of a link, the agency says it "cannot definitively rule out that a small risk may exist," and so will continue research.